巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02367 巨子生物

提前休市 12-24 12:08:29

51.250

-0.050

-0.10%

最高51.800	最低50.700	成交量104.03万
今开51.600	昨收51.300	日振幅2.14%
总市值526.96亿	流通市值526.96亿	总股本10.28亿
成交额5,328万	换手率0.10%	流通股本10.28亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":51.25,"timestamp":1735013309015,"preClose":51.3,"halted":0,"volume":1040297,"delay":0,"floatShares":1028220000,"shares":1028220000,"eps":1.5825987,"marketStatus":"提前休市","marketStatusCode":6,"change":-0.05,"latestTime":"12-24 12:08:29","open":51.6,"high":51.8,"low":50.7,"amount":53281232,"amplitude":0.021442,"askPrice":51.25,"askSize":6000,"bidPrice":51.2,"bidSize":10400,"shortable":3,"etf":0,"ttmEps":1.9133108381842332,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735263000000},"adr":0,"listingDate":1667491200000,"adjPreClose":51.3,"dividendRate":0.020125,"openAndCloseTimeList":[[1735003800000,1735012800000]],"volumeRatio":0.850123,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"2493246282","title":"巨子生物(2367.HK)：骨修复材料创新突破 医美产品未来可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2493246282","media":"西部证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493246282?lang=zh_cn&edition=full","pubTime":"2024-12-22 00:00","pubTimestamp":1734796800,"startTime":"0","endTime":"0","summary":"获批骨修复材料III 类医疗器械注册证，实现严肃医疗领域技术突破。公司自主研发的骨修复材料成功获得国家药监局 III 类医疗器械注册证，为骨缺损修复领域提供了全新解决方案。化妆品表现强势，医美产品未来可期。后续产品上市后将进一步打通化妆品与医美领域的联动路径，为抗衰老和修复市场带来高技术壁垒的创新解决方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222205030a202298a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222205030a202298a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2493425805","title":"国泰君安证券：微信“送礼”功能催化电商进展，有望带来消费新机","url":"https://stock-news.laohu8.com/highlight/detail?id=2493425805","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493425805?lang=zh_cn&edition=full","pubTime":"2024-12-21 22:21","pubTimestamp":1734790897,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国泰君安证券发布研究报告指出，微信小店上线“送礼物”功能，为微信电商生态发展的重要催化。此次小店“送礼”有望成为社群裂变的契机，为中长期微信电商生态发展打下良好用户基础。渠道变革有望带来消费新机，零食、美妆品类及代运营有望受益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","02367","BK0012","BK1207","02611","LU2488822045.USD","BK0201","BK1147","BK0028","BK0188","BK0276","601211","161027","BK1564","BK0184"],"gpt_icon":0},{"id":"2492656144","title":"业绩减速苗头初现，锦波生物难留在舒适圈","url":"https://stock-news.laohu8.com/highlight/detail?id=2492656144","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492656144?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:22","pubTimestamp":1734600160,"startTime":"0","endTime":"0","summary":"作为北交所的明星公司，锦波生物堪称行业典范，业绩前几年稳定高增长，股价最大涨幅超过15倍，盈利水平之高被市场称为“超越茅台的公司”。在医美赛道整体偏弱的情况下，锦波生物独树一帜。不过，从半年报看出，锦波生物旗下主力产品薇旖美收入同比增幅较去年同期出现明显放缓，并且这个赛道中还有巨子生物、江苏吴中、创建医疗等一大批竞争对手，要维持高毛利的同时还要抢占市场，锦波生物能留在舒适圈的时间还有多久？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/247339","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","BK1100","BK1222","09997","09996","BK1583","02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2492142884","title":"巨子生物12月19日遭主力抛售445万元 环比增加1248.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492142884","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492142884?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:15","pubTimestamp":1734596148,"startTime":"0","endTime":"0","summary":"12月19日, 巨子生物股价跌0.38%，报收51.75元，成交金额1.29亿元，换手率0.24%，振幅4.33%，量比0.77。巨子生物今日主力资金净流出445万元，连续3日净流出，上一交易日主力净流出33万元，今日环比增加1248.48%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为35.29%，平均跌幅为2.41%。该股近5个交易日下跌2.53%，主力资金累计净流出872万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入8893万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219162634ab83efc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219162634ab83efc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","BK1207","LU2488822045.USD"],"gpt_icon":0},{"id":"2492114152","title":"巨子生物增资至6.9亿 增幅约110%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492114152","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492114152?lang=zh_cn&edition=full","pubTime":"2024-12-19 14:48","pubTimestamp":1734590901,"startTime":"0","endTime":"0","summary":"南方财经12月19日电，天眼查App显示，近日，巨子生物（HK.02367）发生工商变更，注册资本由约3.3亿人民币增至约6.9亿人民币，增幅约110%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412193273220777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1207","LU2488822045.USD","02367"],"gpt_icon":0},{"id":"2492119611","title":"【券商聚焦】华泰证券升巨子生物(02367)目标价23.5% 指医美产品若获批可能有较大业绩释放潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2492119611","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492119611?lang=zh_cn&edition=full","pubTime":"2024-12-19 14:04","pubTimestamp":1734588293,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发研报指，17日巨子生物 公众号披露获得首个III类医疗器械注册证，为骨修复材料。参考锦波生物、爱美客，后续公司眼部细纹、颈纹产品若能获批可能会带来较大业绩增量。该行预计24-26年归母净利润至19.98/25.10/30.78亿元（维持），可比公司Wind一致盈利预测25PE均值26倍，考虑医美产品若获批可能有较大业绩释放潜力，给予25年28倍PE，目标价HKD73.96元，前值HKD59.89元，维持买入。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367","06886"],"gpt_icon":0},{"id":"2492116956","title":"【券商聚焦】国金证券维持巨子生物(02367)“买入”评级 指其医美明年预期落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2492116956","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492116956?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:58","pubTimestamp":1734587930,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券发研指，巨子生物 近日官网公示，其骨修复材料获批三类医疗器械，符合此前招股书24Q4拿证预期。该行表示，妆品持续完善多单品矩阵，医美明年预期落地。考虑双十一线上表现亮眼，上调公司盈利预测，预计24-26年经调整净利润20.9/25.5/30.6亿元、同增43%/22%/20%，归母净利润20/24.6/29.7亿元，同增38%/23%/21%、对应PE25/20/17倍，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949964","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"gpt_icon":0},{"id":"2492185422","title":"套现近100亿，巨子生物高调上市背后的“资本腾挪”之道","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185422","media":"储凡朋友圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492185422?lang=zh_cn&edition=full","pubTime":"2024-12-18 21:30","pubTimestamp":1734528647,"startTime":"0","endTime":"0","summary":"值得注意的是，巨子生物还在上市前连续三年实施大额分红。换句话说，巨子生物的大股东已经提前将这部分利润进行了“套现”，以免被后续进入的投资人分走。2021年10月13日相关减资及购回股份完成后，西安巨子生物由范博士和GSUM XV HK Holdings Limited分别持有98.91%和1.09%的股本权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218213257ab81eb3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218213257ab81eb3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","02367","LU2488822045.USD"],"gpt_icon":0},{"id":"2492773789","title":"国金证券：维持巨子生物(02367)“买入”评级 骨修复材料获批三类械","url":"https://stock-news.laohu8.com/highlight/detail?id=2492773789","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492773789?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:14","pubTimestamp":1734513264,"startTime":"0","endTime":"0","summary":"事件：国家药监局12月17日官网公示，巨子生物骨修复材料获批三类医疗器械，符合此前招股书24Q4拿证预期。供给端看，据药监局，除巨子生物外，奥精医疗科技、天津市赛宁生物等旗下的胶原蛋白+羟基磷灰石复合的骨修复材料已获批三类械。2)国内获批进展：目前羟基磷灰石材料在国内医美领域尚无合规三类证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"gpt_icon":0},{"id":"2492978136","title":"巨子生物(02367)出现大手成交10.5万股，成交价$51.5，涉资540.75万","url":"https://stock-news.laohu8.com/highlight/detail?id=2492978136","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492978136?lang=zh_cn&edition=full","pubTime":"2024-12-18 14:48","pubTimestamp":1734504480,"startTime":"0","endTime":"0","summary":"[大手成交]巨子生物(02367)在下午02:48出现大手成交，成交量为10.5万，成交价为港币$51.5，涉资540.75万。至目前为止，股价跌0.865%，今日最高价为$52.9，而最低价为$50.8，总成交量为360.25万股，总成交金额港币$1.858亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2412183822/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2492204976","title":"巨子生物(2367.HK)：首个III类医疗器械注册证获批 前景可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2492204976","media":"华泰证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492204976?lang=zh_cn&edition=full","pubTime":"2024-12-18 00:00","pubTimestamp":1734451200,"startTime":"0","endTime":"0","summary":"17 日公司公众号披露获得首个III 类医疗器械注册证，为骨修复材料。另一款颈纹产品近期已进入优先审批绿色通道另据药监局，巨子生物的另外一款医疗器械产品“注射用重组胶原蛋白填充剂”属于“列入国家重点研发计划的医疗器械”，符合优先审批条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218155648ab813a93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218155648ab813a93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1222","02367","09997","BK1207","BK1100","BK1574","BK1583","LU2488822045.USD"],"gpt_icon":0},{"id":"2491147686","title":"巨子生物12月13日获南向资金加仓95.54万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491147686","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491147686?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:30","pubTimestamp":1734312619,"startTime":"0","endTime":"0","summary":"12月13日, 南向资金增持巨子生物95.54万股。截止当日收盘，港股通共持有巨子生物17156.38万股，占流通股16.68%。巨子生物近5个交易日上涨0.68%，港股通累计减持107.22万股；近20个交易日上涨4.34%，港股通累计减持116.41万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093245a1f1a80c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093245a1f1a80c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","LU2488822045.USD","02367"],"gpt_icon":0},{"id":"2491578568","title":"医美赛道迎来一波新玩家！","url":"https://stock-news.laohu8.com/highlight/detail?id=2491578568","media":"青眼","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491578568?lang=zh_cn&edition=full","pubTime":"2024-12-15 20:58","pubTimestamp":1734267480,"startTime":"0","endTime":"0","summary":"欧莱雅集团此举也被视作入局医美赛道的信号，引发行业广泛关注。代表性事件则是欧莱雅集团与颜术医美达成深度合作，进一步为欧莱雅集团旗下修丽可品牌提供研发尖端科技创新。实际上，欧莱雅集团加码医美赛道并非行业首例。而近期刚更名的“丸美生物”，同样在重组胶原赛道进行了一系列布局。医研共创是必经之路美妆企业/品牌会扎堆入局医美赛道并非一蹴而就，这一普遍现象背后实则早已有迹可循。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-15/doc-inczqazp3427773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","02367","BK1222","BK1207","09997","BK1100","BK1583","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2491190983","title":"【券商聚焦】广发证券维持巨子生物(02367)“买入”评级 指医美矩阵丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2491190983","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491190983?lang=zh_cn&edition=full","pubTime":"2024-12-13 13:54","pubTimestamp":1734069264,"startTime":"0","endTime":"0","summary":"该行续指，公司当前市值对应24/25年PE23/18倍，化妆品业务稳健，支撑当前市值，医美预期始终是额外期权。预计公司24-26年归母净利润21.20、26.58、31.74亿元，考虑重组胶原蛋白市场的强增势，给予公司24年25倍PE估值，对应合理价值55.72港元/股，维持“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949614","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01776","02367"],"gpt_icon":0},{"id":"2491839659","title":"港股概念追踪|2024年美妆消费恢复正常购买周期  美妆个护新国货崛起（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2491839659","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491839659?lang=zh_cn&edition=full","pubTime":"2024-12-13 10:09","pubTimestamp":1734055748,"startTime":"0","endTime":"0","summary":"今年“双11”活动期间，珀莱雅旗下各品牌销售情况保持良好态势。丸美天猫旗舰店销售额同比增长34%，稳居天猫国货眼霜第一。国泰君安表示，经历2022年消费承压、2023年消费者端去库存后，2024年美妆消费恢复正常购买周期，行业景气度环比改善，双十一线上美妆实现双位数增长。国泰君安展望2025年市场风险偏好显著修复，美护板块因其变化较多、且国货整体呈崛起趋势，成长属性明显，风格上显著受益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01318","HSTECH","YANG","LU2488822045.USD","02145","BK1207","02367","HSCEI"],"gpt_icon":1},{"id":"1102915591","title":"异动解读 | 巨子生物(02367)获广发买入评级并有医美新药获批,盘中股价大涨6.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102915591","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102915591?lang=zh_cn&edition=full","pubTime":"2024-12-12 16:30","pubTimestamp":1733992237,"startTime":"0","endTime":"0","summary":"巨子生物(02367)股价今日盘中出现大涨行情,大涨6.26%,引发市场关注。分析显示,这主要与两个利好消息有关:\n\n首先,券商广发证券发布研究报告,维持巨子生物\"买入\"评级,预计公司未来3年归母净利润将持续增长,并给予公司合理价值55.72港元的目标价,对公司前景予以看好。\n\n其次,巨子生物旗下针对颈纹的\"注射用重组胶原蛋白填充剂\"获得优先审批。这表明公司在医美领域的创新研发取得进展,为进一步开拓医美市场奠定了基础。据了解,巨子生物目前在医美领域的在研产品共有4款,产品矩阵丰富。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 巨子生物(02367)获广发买入评级并有医美新药获批,盘中股价大涨6.26%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"gpt_icon":0},{"id":"2490434879","title":"广发证券：维持巨子生物(02367)“买入”评级 合理价值55.72港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490434879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490434879?lang=zh_cn&edition=full","pubTime":"2024-12-12 16:25","pubTimestamp":1733991910,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，广发证券发布研究报告称，维持巨子生物“买入”评级，预计2024-26年归母净利润21.20、26.58、31.74亿元，考虑重组胶原蛋白市场的强增势，予24年25倍PE估值，合理价值55.72港元。公司化妆品业务稳健，支撑当前市值，医美预期始终是额外期权。12月5日，巨子生物旗下的“注射用重组胶原蛋白填充剂”获得优先审批，“该产品属于列入国家重点研发计划的医疗器械”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","01776"],"gpt_icon":0},{"id":"2490820737","title":"巨子生物盘中异动 下午盘急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490820737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490820737?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:02","pubTimestamp":1733986957,"startTime":"0","endTime":"0","summary":"2024年12月12日下午盘15时02分，巨子生物股票出现异动，股价快速拉升5.07%。截至发稿，该股报52.850港元/股，成交量308.342万股，换手率0.30%，振幅6.36%。巨子生物股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，思路迪医药股份、晶泰控股-P、帝王国际投资涨幅较大，振幅较大的相关个股有思路迪医药股份、晶泰控股-P、帝王国际投资，振幅分别为38.70%、19.44%、18.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121215023795e923d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121215023795e923d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","BK1207","LU2488822045.USD"],"gpt_icon":0},{"id":"2490787428","title":"巨子生物(02367)上涨5.07%，报52.85元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490787428","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490787428?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:02","pubTimestamp":1733986944,"startTime":"0","endTime":"0","summary":"12月12日，巨子生物(02367)盘中上涨5.07%，截至15:02，报52.85元/股，成交1.59亿元。巨子生物主营业务为研发和生产功效性护肤品、医疗器械和功能性食品，核心技术是采用自有的合成生物学技术开发重组胶原蛋白和稀有人参皂苷等生物活性成分。公司拥有93项专利和专利申请，其重组胶原蛋白技术在中国是首个获得专利的，并曾两次获得重要的技术奖励。截至2024年中报，巨子生物营业总收入25.4亿元、净利润9.83亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/12150246307014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2490846783","title":"南向资金12月11日净卖出巨子生物3.86万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2490846783","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490846783?lang=zh_cn&edition=full","pubTime":"2024-12-12 09:30","pubTimestamp":1733967023,"startTime":"0","endTime":"0","summary":"12月11日，南向资金减持巨子生物3.86万股连续3日减持。截止当日收盘，港股通共持有巨子生物17065.54万股，占流通股16.58%。巨子生物近5个交易日上涨2.86%，港股通累计减持206.58万股；近20个交易日下跌1.76%，港股通累计减持331.08万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212093230ab710123&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212093230ab710123&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","BK1207","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":0.0364},{"period":"3month","weight":0.2825},{"period":"6month","weight":0.1312},{"period":"1year","weight":0.5795},{"period":"ytd","weight":0.4708}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0464},{"period":"6month","weight":0.0991},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.1663}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家中国的投资控股公司。该公司通过其子公司主要从事基于生物活性材料的美容和健康产品的研发、生产和销售。该公司的主要产品包括功能性护肤品和医用敷料，其产品的关键生物活性成分为重组胶原蛋白。该公司还开发和生产基于人参皂苷技术的稀有功能食品。该公司主要在国内市场开展其业务。","exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}